Clinical Trial Update: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of ARX517/JNJ-95298177 as monotherapy or in combination for metastatic prostate cancer. The trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ARX517/JNJ-95298177 (ARX517)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Metastatic Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING